安科生物：公司参股公司博生吉公司创新药物的海外授权工作持续推进中

Core Viewpoint - Anke Bio (300009) is actively advancing the overseas licensing of innovative drugs through its subsidiary, Boshengji, and will disclose results appropriately when available [1] Group 1: Company Developments - The company is focusing on companies that utilize AI platform technology as a core technology [1] - The review of Longpei growth hormone is nearing completion with the National CDE [1]